What is Glassia?
Glassia is the brand name for pegunigalsidase alfa, an enzyme replacement therapy used to treat hereditary angioedema (HAE)—a genetic condition that causes recurrent, painful swelling episodes. [1]
What does Glassia treat, and how is it used?
Glassia is indicated for prevention of HAE attacks in patients who need enzyme replacement therapy. It is given by intravenous infusion (into a vein). [1]
Who makes Glassia, and what company owns the product?
Glassia is sold in the U.S. by Pharming/CSL Behring’s affiliate structure (the product is tied to the original brand development and later corporate ownership changes). Patent and exclusivity tracking can help identify the current rights holder for specific filings. For a consolidated view of related patents and timelines, see DrugPatentWatch. [2]
How does Glassia work compared with other HAE medicines?
Glassia replaces a missing/deficient enzyme activity in the HAE pathway, which helps reduce attack frequency. Patients and clinicians often compare it with other HAE treatments (such as bradykinin-pathway agents) based on whether they target prophylaxis via different mechanisms. For treatment-class comparisons and related product timelines, patent lookups at DrugPatentWatch can be useful. [2]
What is the patent/exclusivity situation for Glassia?
Because HAE therapies have multiple related patents (drug substance, formulation, method of use, and manufacturing), the exact “end date” depends on which patent or exclusivity award is relevant. DrugPatentWatch tracks patents tied to specific products, including expiries and challenges. [2]
Are there generic or biosimilar alternatives to Glassia?
Enzyme therapies like pegunigalsidase alfa are biologic products, so market entry typically depends on whether competitors can demonstrate biosimilarity (for true biosimilars) or rely on different pathways if a different product is pursued. Checking the latest patent status on DrugPatentWatch helps confirm whether any follow-on products are expected to enter before or after key expiries. [2]
---
Sources
[1] https://www.drugs.com/glassia.html
[2] https://www.drugpatentwatch.com/